期刊名称：FEBS LETTERS
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
FEBS Letters is published by Elsevier on behalf of the Federation of European Biochemical Societies
Sponsored Articles
FEBS Letters offers authors the option to sponsor non-subscriber access to their articles on Elsevier's electronic publishing platforms. For more information please view our Sponsored Articles page.
FEBS Letters is one of the world's leading journals in biochemistry and is renowned both for its quality of content and speed of production. Bringing together the most important developments in the molecular biosciences, FEBS Letters provides an international forum for Minireviews, hypotheses and research ... click here for full Aims & Scope
FEBS Letters is one of the world's leading journals in biochemistry and is renowned both for its quality of content and speed of production. Bringing together the most important developments in the molecular biosciences, FEBS Letters provides an international forum for Minireviews, hypotheses and research letters that merit urgent publication.
FEBS Letters offers:
• Faster publication:
− Accepted articles are published online in 3 days
− The print version of the article is published in 3 to 5 weeks after acceptance
• Full-text article disclosure in HTML and PDF formats
• Articles in Press are included in PubMed
• Easy online manuscript submission system
• Transparent online peer review and manuscript tracking system
• No page charges
• Free color figures
Subject Coverage:
The subject area of FEBS Letters is broad. It covers biochemistry (including protein chemistry, enzymology, nucleic acid chemistry, metabolism, and immunochemistry), structural biology, biophysics, computational biology (genomics, proteomics, bioinformatics), molecular genetics, molecular biology and molecular cell biology (signal transduction, intracellular traffic, regulation of cellular proliferation, cell-cell interactions) and systems biology. Studies on microbes, plants and animals at the molecular level are within the scope of FEBS Letters.
Instructions to Authors
Types of paper
Reviews, Hypotheses and Research Letters
Contact details for submission
Papers should be submitted using the FEBS Letters online submission system, http://ees.elsevier.com/febsletters. For questions on the submission or reviewing process, please contact the Editorial Office prior to submission at febs.letters@bzh.uni-heidelberg.de
Page charges
This journal has no page charges.
Ethics in Publishing
For information on Ethics in Publishing and Ethical guidelines for journal publication see http://www.elsevier.com/publishingethics and http://www.elsevier.com/ethicalguidelines.
Policy and ethics
The work described in your article must have been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/e/policy/b3.htm; EC Directive 86/609/EEC for animal experiments http://ec.europa.eu/environment/chemicals/lab_animals/legislation_en.htm; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. This must be stated at an appropriate point in the article.
Conflict of interest
All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the submitted work that could inappropriately influence, or be perceived to influence, their work. See also http://www.elsevier.com/conflictsofinterest.
Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection software iThenticate. See also http://www.elsevier.com/editors/plagdetect.
Authorship
All authors should have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted.
Copyright
Upon acceptance of an article, the author(s) will be asked to transfer copyright of the article to the Federation of European Biochemical Societies. This transfer will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.
Authors or a third party wishing to reproduce figures, tables or brief quotations from the text of articles published in FEBS Letters for non-commercial purposes may do so, providing the original publication is acknowledged accordingly and the authors' approval is obtained. No special permission is needed from FEBS, the Publisher or the Managing Editor for this. If authors or a third party wish to use a major part of an article or an entire article elsewhere, whether in English or any translation, permission must be asked from the Publisher, who will if necessary contact FEBS, the copyright holder.
Useful links: http://www.elsevier.com/copyright
http://www.elsevier.com/permissions
Retained author rights
As an author you (or your employer or institution) retain certain rights; for details you are referred to: http://www.elsevier.com/authorsrights.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement then this should be stated. Please see http://www.elsevier.com/funding.
Funding body agreements and policies
FEBS Letters complies with current NIH public access policy
Sponsored articles
Worldwide approximately 10 million scientists, faculty members and graduate students can access FEBS Letters through institutional subscriptions. In addition, Elsevier's ScienceDirect licenses permit all public users who are permitted by the library to walk in and use its resources to access all journals to which the institution subscribes. In a few instances, authors have requested to make their articles freely available online to all non-subscribers. FEBS Letters offers authors the option to sponsor an article and make it available online to non-subscribers via ScienceDirect. Authors can only select this option after receiving notification that their article has been accepted for publication. This prevents a potential conflict of interest where FEBS Letters would have a financial incentive to accept an article.
The author charge for article sponsorship is $3,000. This charge is necessary to offset publishing costs - from managing article submission and peer review, to typesetting, tagging and indexing of articles, hosting articles on dedicated servers, supporting sales and marketing costs to ensure global dissemination via ScienceDirect, and permanently preserving the published journal article. The fee excludes taxes and other potential author fees such as optional charges for extra reprints which are additional.
Authors who have had their article accepted and who wish to sponsor their article to make it available to non-subscribers should complete and submit the order form: http://www.elsevier.com/framework_authors/Sponsoredarticles/sponsoredarticleoption.pdf
Language and language services
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who require information about language editing and copyediting services pre- and post-submission please visit http://www.elsevier.com/languageediting or our customer support site at http://epsupport.elsevier.com for more information.
Submission
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail removing the need for a paper trail.
Referees
Please submit, with the manuscript, the names, addresses and e-mail addresses of potential referees. Note that the editor retains the sole right to decide whether or not the suggested reviewers are used.
Additional information
Fast-Track Publication
FEBS Letters offers expedited handling of manuscripts that have been rejected from very high-level journals. Authors should enclose reviews and/or comments from the editor of previously reviewed manuscripts to expedite their handling as your manuscript may be accepted based on the previous reviews. You will receive a final decision from the Managing Editor within a few days of submitting manuscripts with reviews.
Use of wordprocessing software
It is important that the file be saved in the native format of the wordprocessor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the wordprocessor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. Do not embed "graphically designed" equations or tables, but prepare these using the wordprocessor's facility. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier: http://www.elsevier.com/guidepublication). Do not import the figures into the text file but, instead, indicate their approximate locations directly in the electronic text and on the manuscript. See also the section on Electronic illustrations.
To avoid unnecessary errors you are strongly advised to use the "spell-check" and "grammar-check" functions of your wordprocessor.
Article structure
Subdivision - numbered sections
Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to "the text". Any subsection may be given a brief heading. Each heading should appear on its own separate line.
Introduction
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Material and methods
Provide sufficient detail to allow the work to be reproduced. Methods already published should be indicated by a reference: only relevant modifications should be described.
Results
Results should be clear and concise.
Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.
Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.
Appendices
If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on.
Essential title page information
• Title. Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
• Author names and affiliations. Where the family name may be ambiguous (e.g., a double name), please indicate this clearly. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name, and, if available, the e-mail address of each author.
• Corresponding author. Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. Ensure that telephone and fax numbers (with country and area code) are provided in addition to the e-mail address and the complete postal address.
• Present/permanent address. If an author has moved since the work described in the article was done, or was visiting at the time, a "Present address" (or "Permanent address") may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.
Abstract
A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.
Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.
Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.
Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).
Nomenclature and units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other quantities are mentioned, give their equivalent in SI. You are urged to consult IUB: Biochemical Nomenclature and Related Documents: http://www.chem.qmw.ac.uk/iubmb/ for further information.
Accession numbers
Accession numbers are unique identifiers in bioinformatics allocated to nucleotide and protein sequences to allow tracking of different versions of that sequence record and the associated sequence in a data repository [e.g., databases at the National Center for Biotechnical Information (NCBI) at the National Library of Medicine ('GenBank') and the Worldwide Protein Data Bank]. There are different types of accession numbers in use based on the type of sequence cited, each of which uses a different coding. Authors should explicitly mention the type of accession number together with the actual number, bearing in mind that an error in a letter or number can result in a dead link in the online version of the article. Please use the following format: accession number type ID: xxxx (e.g., MMDB ID: 12345; PDB ID: 1TUP). Note that in the final version of the electronic copy, accession numbers will be linked to the appropriate database, enabling readers to go directly to that source from the article.
Math formulae
Present simple formulae in the line of normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).
Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article, using superscript Arabic numbers. Many wordprocessors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.
Table footnotes
Indicate each footnote in a table with a superscript lowercase letter.
Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Save text in illustrations as "graphics" or enclose the font.
• Only use the following fonts in your illustrations: Arial, Courier, Times, Symbol.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Provide captions to illustrations separately.
• Produce images near to the desired size of the printed version.
• Submit each figure as a separate file.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalised, please "save as" or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):
EPS: Vector drawings. Embed the font or save the text as "graphics".
TIFF: color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF: Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF: Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi is required.
DOC, XLS or PPT: If your electronic artwork is created in any of these Microsoft Office applications please supply "as is".
Please do not:
• Supply embedded graphics in your wordprocessor (spreadsheet, presentation) document;
• Supply files that are optimised for screen use (like GIF, BMP, PICT, WPG); the resolution is too low;
• Supply files that are too low in resolution;
• Submit graphics that are disproportionately large for the content.
Color artwork
Please make sure that artwork files are in an acceptable format (TIFF, EPS or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color on the Web (e.g., ScienceDirect and other sites) in addition to color reproduction in print. For further information on the preparation of electronic artwork, please see http://www.elsevier.com/artworkinstructions.
Figure captions
Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.
Tables
Number tables consecutively in accordance with their appearance in the text. Place footnotes to tables below the table body and indicate them with superscript lowercase letters. Avoid vertical rules. Be sparing in the use of tables and ensure that the data presented in tables do not duplicate results described elsewhere in the article.
References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either "Unpublished results" or "Personal communication" Citation of a reference as "in press" implies that the item has been accepted for publication.
Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.
References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.
Reference management software
This journal has standard templates available in key reference management packages EndNote ( http://www.endnote.com) and Reference Manager ( http://www.refman.com). Using plug-ins to wordprocessing packages, authors only need to select the appropriate journal template when preparing their article and the list of references and citations to these will be formatted according to the journal style which is described below.
Reference style
Text: Indicate references by number(s) in square brackets in line with the text. The actual authors can be referred to, but the reference number(s) must always be given.
Example: "..... as demonstrated [3,6]. Barnaby and Jones [8] obtained a different result ...."
List: Number the references (numbers in square brackets) in the list in the order in which they appear in the text.
Examples:
Reference to a journal publication:
Reference to a journal publication: [1] MacKinnon, R. (2003). Potassium channels. FEBS Lett. 555, 62-5.
[2] Hardie, D.G., Scott, J.W., Pan, D.A., and Hudson, E.R. (2003). Management of cellular energy by the AMP-activated protein kinase system. FEBS Lett. 546, 113-120.
Reference to a chapter in an edited book:
[3].Langer, T. and Neupert, W. (1994) Chaperoning mitochondrial biogenesis. In The Biology of Heat Shock Proteins and Molecular Chaperones (Morimoto, R.I., Tissieres, A. and Georgopoulos, C., eds), pp. 53-83. Cold Spring Harbor Laboratory Press, Plainview, NY.
[4] Feldmann, H. (2004) Forty years of FEBS, Blackwell Publishing Ltd. Oxford.
Journal abbreviations source
Journal names should be abbreviated according to
Index Medicus journal abbreviations: http://www.nlm.nih.gov/tsd/serials/lji.html;
List of serial title word abbreviations: http://www.issn.org/2-22661-LTWA-online.php;
CAS (Chemical Abstracts Service): http://www.cas.org/sent.html.
Video data
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats with a maximum size of 10 MB. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages at http://www.elsevier.com/artworkinstructions. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.
Supplementary data
Elsevier accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips and more. Supplementary files supplied will be published online alongside the electronic version of your article in Elsevier Web products, including ScienceDirect: http://www.sciencedirect.com. In order to ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file. For more detailed instructions please visit our artwork instruction pages at http://www.elsevier.com/artworkinstructions.
Submission checklist
It is hoped that this list will be useful during the final checking of an article prior to sending it to the journal's Editor for review. Please consult this Guide for Authors for further details of any item.
Ensure that the following items are present:
One Author designated as corresponding Author:
• E-mail address
• Full postal address
• Telephone and fax numbers
All necessary files have been uploaded
• Keywords
• All figure captions
• All tables (including title, description, footnotes)
Further considerations
• Manuscript has been "spellchecked" and "grammar-checked"
• References are in the correct format for this journal
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)
• Color figures are clearly marked as being intended for color reproduction on the Web (free of charge) and in print or to be reproduced in color on the Web (free of charge) and in black-and-white in print
• If only color on the Web is required, black and white versions of the figures are also supplied for printing purposes
For any further information please visit our customer support site at http://epsupport.elsevier.com.
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly 'Articles in press' because they have not yet received their full bibliographic information. The correct format for citing a DOI is shown as follows (example taken from a document in the journal Physics Letters B):
doi:10.1016/j.physletb.2003.10.071
When you use the DOI to create URL hyperlinks to documents on the web, they are guaranteed never to change.
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in the e-mail so that authors can download the files themselves. Elsevier now provides authors with PDF proofs which can be annotated; for this you will need to download Adobe Reader version 7 (or higher) available free from http://www.adobe.com/products/acrobat/readstep2.html. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/acrobat/acrrsystemreqs.html#70win.
If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If, for any reason, this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. We will do everything possible to get your article published quickly and accurately. Therefore, it is important to ensure that all of your corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.
Corrections should be returned within 48 hours. Thereafter, proofs will be processed and included in the first available issue. Late corrections cannot be accepted.
Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail or, alternatively, 25 free paper offprints. If the corresponding author opts for paper offprints, this preference must be indicated via the offprint order form which is sent once the article is accepted for publication. Additional paper offprints can also be ordered via this form for an extra charge. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.
For inquiries relating to the submission of articles (including electronic submission where available) please visit this journal's homepage. You can track accepted articles at http://www.elsevier.com/trackarticle and set up e-mail alerts to inform you of when an article's status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher.
Editorial Board
Managing Editor:
Felix Wieland
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, Email: felix.wieland@bzh.uni-heidelberg.de
Editorial Manager:
P. McCabe
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
Assistant Editors:
Aleksander Benjak
, Email: aleksander.benjak@bzh.uni-heidelberg.de
Daniela Ruffell
, Email: daniela.ruffell@bzh.uni-heidelberg.de
Former Managing Editors:
Professor S.P. Datta
London, UK
Professor G. Semenza
Zollikon ZH, Switzerland
Editors:
Jesus Avila
Universidad Autónoma de Madrid, Madrid, Spain, Email: javila@cbm.uam.es
Robert Barouki
Université Paris Descartes, Paris cedex 06, France, Email: robert.barouki@biomedicale.univ-paris5.fr
Peter Brzezinski
Stockholms Universitet, Stockholm, Sweden, Email: peterb@dbb.su.se
Michael Bubb
University of Florida, Gainesville, FL, USA, Email: bubbmr@medicine.ufl.edu
Gianni Cesareni
Università di Roma "Tor Vergata", Rome, Italy, Email: cesareni@uniroma2.it
Zhijie Chang
Tsinghua University, Beijing, China, Email: zhijiec@tsinghua.edu.cn
Quan Chen
Chinese Academy of Sciences (CAS), Beijng, China, Email: chenquan@nankai.edu.cn
Richard Cogdell
University of Glasgow, Glasgow, UK, Email: r.cogdell@bio.gla.ac.uk
Hans Eklund
Uppsala Universitet, Uppsala, Sweden, Email: hasse@xray.bmc.uu.se
Stuart Ferguson
University of Oxford, Oxford, UK, Email: ferguson@bioch.ox.ac.uk
Ulf-Ingo Flügge
Universität zu Köln, Köln, Germany, Email: ui.fluegge@uni-koeln.de
Takashi Gojobori
National Institute of Genetics, Mishima, Shizuoka, Japan, Email: tgojobor@genes.nig.ac.jp
Christian Griesinger
Max Planck Institut (MPI) für Biophysikalische Chemie, Göttingen, Germany, Email: cigr@nmr.mpibpc.mpg.de
Lukas Huber
Leopold-Franzens-Universität Innsbruck, Innsbruck, Austria, Email: Lukas.A.Huber@uibk.ac.at
Michael Ibba
The Ohio State University, Columbus, OH, USA, Email: ibba.1@osu.edu
Beat Imhof
Université de Genève, Centre Medical Universitaire (CMU), Geneva 4, Switzerland, Email: Beat.Imhof@medecine.unige.ch
Hans-Dieter Klenk
Universität Marburg, Marburg, Germany, Email: klenk@mailer.uni-marburg.de
Jacomine Krijnse-Locker
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, Email: jacomine.krijnse@bioquant.uni-heidelberg.de
Ulrike Kutay
Eidgenössische Technische Hochschule Zürich (ETH), Zürich, Switzerland, Email: Kutay.febs@bc.biol.ethz.ch
Veli-Pekka Lehto
University of Helsinki, Helsinki, Finland, Email: pekka.lehto@helsinki.fi
Kaspar Locher
Eidgenössische Technische Hochschule Zürich (ETH), Zürich, Switzerland, Email: locher@mol.biol.ethz.ch
Dietmar J. Manstein
Hannover Medical School (MHH), Hannover, Germany, Email: manstein@bcp.mh-hannover.de
Ned Mantei
Eidgenössische Technische Hochschule Zürich (ETH), Zürich, Switzerland, Email: mantei@cell.biol.ethz.ch
Masayuki Miyasaka
Osaka University, Suita-Shi, Japan, Email: mmiyasak@orgctl.med.osaka-u.ac.jp
Maurice Montal
University of California at San Diego (UCSD), La Jolla, CA, USA, Email: montal@biomail.ucsd.edu
Laszlo Nagy
University of Debrecen, Debrecen, Hungary, Email: nagyl@med.unideb.hu
Angel Nebreda
Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain, Email: anebreda@cnio.es
Judit Ovádi
Hungary Academy Science, XI. Kerület, Budapest, Hungary, Email: ovadi@enzim.hu
Varda Rotter
Weizmann Institute of Science, Rehovot, Israel, Email: varda.rotter@weizmann.ac.il
Rob(ert) Russell
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, Email: robert.russell@bioquant.uni-heidelberg.de
Ivan Sadowski
University of British Columbia, Vancouver, BC, Canada, Email: sadowski@interchange.ubc.ca
Julian Schröder
University of California at San Diego (UCSD), San Diego, USA, Email: Julian@biomail.ucsd.edu
Irmgard Sinning
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, Email: sinning@embl-heidelberg.de
Vladimir Skulachev
M. V. Lomonosov Moscow State University, Moscow, Russian Federation, Email: skulach@genebee.msu.su
Sandro Sonnino
Università degli Studi di Milano, Segrate (Mi), Italy, Email: Sandro.Sonnino@unimi.it
Bing Sun
Chinese Academy of Sciences (CAS), Shanghai, China, Email: bingsun@sunm.shcnc.ac.cn
Giulio Superti-Fuga
Österreichische Akademie der Wissenschaften, Vienna, Austria, Email: Giulio.Superti-Furga@cemm.oeaw.ac.at
Michael Sussman
University of Wisconsin at Madison, Madison, WI, USA, Email: msussman@wisc.edu
Renee Tsolis
University of California at Davis, Medical Center, Davis, CA, USA, Email: rmtsolis@ucdavis.edu
Berend Wieringa
Universitair Medisch Centrum Nijmegen St Radboud, Nijmegen, Netherlands, Email: b.wieringa@ncmls.ru.nl
Miguel De la Rosa
Consejo Superior de Investigaciones Científicas (CSIC), Sevilla, Spain, Email: marosa@us.es
Paul Bertone
European Bioinformatics Institute, Cambridge, UK, Email: bertone@ebi.ac.uk
Tamas Dalmay
University of East Anglia, Norwich, UK, Email: T.Dalmay@uea.ac.uk
Barry Halliwell
National University of Singapore (NUS), Singapore, Singapore, Email: bchbh@nus.edu.sg
Wilhelm Just
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, Email: wilhelm.just@bzh.uni-heidelberg.de
Noboru Mizushima
Tokyo Medical and Dental University, Bunkyo-Ku, Japan, Email: nmizu.phy2@tmd.ac.jp
Francesc Posas
Universitat Pompeu Fabra (UPF), Barcelona, Spain, Email: francesc.posas@upf.edu
Felix Wieland
Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany, Email: felix.wieland@bzh.uni-heidelberg.de
| 
刊名字顺( Alphabetical List of Journals):
返回页首 